Dairy heifers were treated 0 to 90 d, 90 to 180 d, or 180 to 270 d prepartum with one of five different antibiotic products to determine the best time and with which product they should be treated prior to calving. Two hundred thirty-three heifers were included in the study. At the initial sampling, 56.5% of quarters were infected with some type of organism and 15.4% of quarters were infected with Staphylococcus aureus. Treatments included a cephapirin dry cow product, a penicillin-novobiocin dry cow product, a penicillin-streptomycin dry cow product, an experimental dry cow product containing tilmicosin, and a cephalonium dry cow product not available in the United States. Cure rates for the five antibiotic products indicated that all were equally effective against Staph. aureus and all were significantly more effective than the spontaneous cure rate observed in untreated control quarters. No differences in efficacy were observed due to the different treatment times prepartum. However, fewer new Staph. aureus infections occurred after treatment in the group treated at 180 to 270 d prepartum, indicating that treatment in the third trimester will reduce the chances of new intramammary infections occurring after treatment and persisting to calving.
INTRODUCTION
It is now understood that dairy heifers are at risk for developing mastitis early in life, even before attaining breeding age. Studies have documented mastitis in heifers as young as 9 mo of age, and investigations have 1 1Approved for publication by the Director of the Louisiana Agricultural Experiment Station as manuscript number 00-80-0319.
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shown that infection rates can be as high as 97% (Nickerson, et al. 1995) . The staphylococci are the predominant mastitis pathogens causing heifer mastitis, and Staphylococcus aureus can represent a substantial percentage of these infections. Because Staph. aureus is a major mastitis pathogen for the dairy industry, and because it is very difficult to cure once established in lactating cows, its presence in heifers is of great concern. Staphylococcus aureus mastitis in dairy heifers can persist through the prepartum period and into the first lactation. The resulting damage to developing mammary tissue can reduce milk production and cause the heifer to fail in reaching her maximum milk production potential.
Therapy studies employing antibiotic preparations administered prior to calving have reported excellent cure rates for Staph. aureus mastitis in heifers (Owens, et. al., 1993; Trinidad, et. al., 1990) . Times of treatment for these studies have ranged from 1 to 2 wk to several months prepartum and have employed a variety of dry cow and lactating cow preparations. No clear consensus has been drawn from these studies as to which time of treatment or which antibiotic preparation is best.
To answer these questions, four different antibiotic preparations were tested during the first (0 to 90 d), second (90 to 180 d), and third (180 to 270 d) trimester of pregnancy to determine which antibiotic and which treatment time was best. A fifth antibiotic preparation was tested during the first trimester only.
METHODS
Jersey heifers from the Hill Farm Research Station, Louisiana, were sampled and enrolled in the study at various times prepartum. Secretion samples were collected into sterile tubes. Each teat end was examined for abnormalities, and the teat meatus was sanitized by scrubbing with cotton balls moistened with 70% ethanol. If no secretion was present, a streak canal swab sample was collected aseptically. Once the meatus was visibly clean, the tip of an ultra fine aluminum shaft cotton swab (Calgiswab, type 4; Spectrum Laboratories, Inc., Houston, TX) was inserted approximately 2 mm and gently rotated 360°against the teat canal wall to obtain a sample. After removal, the swab was placed in a 12-× 75-mm polystyrene culture tube containing 0.5 ml of sterile physiological saline. Only single samples were obtained to minimize potential trauma to teat canal tissues. Secretion samples were collected in 17-× 100-mm polystyrene tubes and examined for abnormalities (i.e., clots, flakes, and blood). Only single samples were obtained due to limited volume of quarter secretions in most animals. Both teat canal samples and secretion samples were refrigerated in portable ice chests until arrival at the laboratory. Secretion samples were subdivided into two main categories based on appearance and viscosity. Thin, watery, milky, or whey like samples were combined as one type. Viscous honeylike samples were a second type and colostrum-like samples were a third type. Assignment to a category was based on observations made at the time of plating samples to culture media. Samples consisting of streak canal swabs only were not categorized. At the initial sampling, teats were observed for the presence of scabbing, fly bites, or abrasions. Teat canal samples were vortexed for 10 s, and 0.1 ml was plated onto trypticase soy blood agar plates (TBA, BBL Microbiology Systems, Cockeysville, MD) containing 0.1% esculin (Sigma Chemical Co., St. Louis, MO) and 5% calf blood. Quarter samples were plated on TBA. Plates were incubated at 37°C and colony characteristics and numbers of colonyforming units were recorded at 48 h. Gram stain and culture characteristics on TBA (i.e., colony morphology, pigmentation, aroma, hemolysis, and catalase production) were used for presumptive identification for all isolates (Pankey, et al. 1984) . Species identification of staphylococci was performed using the API Staph-Trac system (Analytab Products, Plainview, NY). Streptococci were identified as by Watts (1988) .
After the initial sampling, heifers were randomly assigned to one of five treatment groups (culture results did not affect assignment): 1) untreated controls, 2) nonlactating cow product containing 300 mg of cephapirin benzathine (Tomorrow, Fort Dodge Animal Health, Fort Dodge, IA), 3) nonlactating cow product containing 1 million units penicillin and 1 gm of streptomycin (Quartermaster, Pharmacia Upjohn, Kalamazoo, Michigan), 4) nonlactating cow product containing 200,000 units of penicillin and 400 mg of novobiocin (Albadry Plus, Pharmacia Upjohn, Kalamazoo, Michigan), and 5) an experimental product containing 300 mg of tilmicosin (Micotil, Eli Lilly and Co., Indianapolis, Indiana). A nonlactating cow product containing 250 mg of cephalonium (Cefasafe, Intervet, Boxmeer, Holland) was tested on an additional group of cows (group 6) treated during the first trimester. Initial sampling for all groups occurred shortly after animals were confirmed pregnant and continued at 4-wk intervals thereafter. Within each treatment group, (except group 6) animals were treated during the first (0 to 90 d), second (90 to 180 d), or third (180 to 270 d) trimester of pregnancy with one intramammary infusion of the selected antibiotic into each quarter. Treatment with tilmicosin was purely experimental. It is not labeled for use as an intramammary infusion product. The cephalonium product is currently not available in the United States.
All quarters of each heifer were treated with the assigned antibiotic using the manufactures infusion syringes. For tilmicosin, the antibiotic was infused with 5-cc syringes fitted with standard infusion canulas (Genesis Industries, Elmwood, WI). Partial insertion of the canulas was used to prevent damage to teat ends. No problem infusing the 10-ml volume into heifer mammary glands was observed. Secretions from heifers were considered positive for bacterial infection when a pure culture of more than five colonies was present for Staphylococcus species and Streptococcus species. The presence of any Staph. aureus colonies was considered positive. Secretions positive for a bacterial infection typically harbored large numbers (20 to >100 colonies) of the infecting organism in pure culture.
Prepartum infections in heifers were considered cured if duplicate quarter samples were bacteriologically negative at parturition. Infected quarters that had new infections at parturition with a different organism after treatment of the original infections were considered cures for the original infection.
Statistical differences between treatment groups and untreated controls were determined by a normal approximation with Student's t-test (Trindad et al., 1990) .
RESULTS AND DISCUSSION
Two hundred thirty-three heifers were included in the study. At the initial sampling, 56.5% of quarters were infected. The predominant organisms were staphylococci, with Staph. aureus infecting 15.4% of quarters. The range of Staph. aureus-infected quarters among the five treatment groups was 8.3 to 27% (Figure 1) . In untreated control quarters, the percentage of quarters infected with Staph. aureus remained above 20% through much of the prepartum period, and decreased to 8.3% at calving (Table 1) . Among treated quarters, the percentage infected with Staph. aureus dropped below 5% after treatment and remained low through calving (Figure 1) . Cure rates among treatments indicated all that antibiotic preparations tested were equally effective and there was no observed effect of time of treatment before calving (Figure 2) . Prevalence of Staph. aureus was found to be approximately twice as high (6.9 vs. 12.2%) in quarters with teats having scabs or abrasions. Other IMI were not associated with scabs or lesions. Cure rates for the coagulase-negative staphylococci and Streptococcus species are in Table 2 .
Results were similar to those seen with Staph. aureus, cure rates were high and ranged from 80 to 100%. No difference in cure rates among the treatments was noted for the coagulase-negative staphylococci or the Streptococcus species. Secretion consistency was found to be associated with prevalence of intramammary infection. Quarters with thin (31%), milky (42.5%), or whey-like (52.6%) secretions were more likely to be infected than quarters with viscous honey-like (8.3%) or colostrum-like (11.7%) secretions. Cure rates for the cephalonium product are in Table  3 . Cephalonium administered as a dry cow product in the first trimester cured 100% of treated Staph. aureus IMI and 85% of Staphylococcus species IMI. No animals were treated with this product in the second or third trimester. Six new Staph. aureus IMI occurred in the cephalonium group after therapy in the first trimester. This approximates the new IMI rate for the other treatments.
No difference in efficacy of the different antibiotics tested was observed, nor did the timing of treatment before parturition have an effect on efficacy (Figure 2). However, it was noted that no new Staph. aureus infections occurred during the third trimester in any of the groups (Table 4) . Therefore, waiting until the third trimester reduces the chance that new infections will occur after antibiotic therapy is completed. Treatment at approximately 60 to 45 d prepartum will allow sufficient time for residues to dissipate before calving and ensure that maximum numbers of infections are treated.
The treatment of heifers known to be at risk for developing Staph. aureus mastitis is advantageous because the expected cure rate is much higher than cure rates obtained when treating infections in lactation. In previous studies, cure rates of Staph. aureus infections in heifers exceeded 90% when treatment was administered prepartum, while cure rates during lactational therapy were approximately 50% (Owens et al. 1991 (Owens et al. , 1993 . In addition, there is no loss of milk, the risk of antibiotic residue in milk at calving is minimal, and future milk production is increased in cows cured of Staph. aureus mastitis (Owens et al., 1991) .
CONCLUSIONS
Staphylococcus aureus is a major mastitis pathogen that can cause significant mastitis in dairy heifers. Antibiotic therapy prepartum was very effective against mastitis in heifers, and this study indicated that time of treatment prepartum had no effect. Likewise, all antibiotic preparations tested performed equally well.
Fewer new infections occurred in the third trimester; therefore, treatment during the third trimester will reduce the chances of new infections occurring after prepartum treatment.
